Why Viking Therapeutics Stock Got Mashed on Monday
Investors didn't exactly launch a raid on Viking Therapeutics (NASDAQ: VKTX) stock during Monday's trading session. The shares tumbled by nearly 7% on the back of discouraging news about one of the company's drug candidates.
Viking, a clinical-stage biotech that concentrates on metabolic and endocrine disorders, announced that its VK0214 program has been put on ice for now by the Food and Drug Administration (FDA).
Image source: Getty Images.
Source Fool.com
